Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) presented five studies at the annual American College of Rheumatology Convergence 2023, reinforcing the safety and effectiveness of LUPKYNIS® (voclosporin) for the treatment of adult patients with active lupus nephritis. The studies showed that initial therapy with LUPKYNIS® plus standard of care improved safety and demonstrated earlier reductions in proteinuria compared to a conventional regimen. The data also showed an improved safety profile over the first six months of treatment with LUPKYNIS® in combination with low-dose glucocorticoids and lower-dose MMF without compromising efficacy.